Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin Shoppe, Vitacost.com Emerge From IPOs With Healthy Sales

This article was originally published in The Tan Sheet

Executive Summary

A pair of supplement retailers report strong sales growth during their first quarterly earnings calls as publicly traded companies, supporting the notion that many consumers consider nutritional products non-discretionary purchases

You may also be interested in...



Sales & Earnings In Brief

Afexa rides flu concerns to record Q1: The maker of Cold-FX reports record revenue of $27.7 million (Canadian $29.5 million at Feb. 11 exchange rates), a 49.7 percent increase, during the quarter ended Dec. 31. Net earnings were also up substantially - 142.9 percent to $6.4 million - in Afexa Life Sciences' fiscal 2010 first quarter. Jack Moffatt, CEO of the Edmonton, Alberta, company, attributed increased sales of Cold-FX to public flu concerns, though "we expect demand to moderate in the second quarter" as cold and flu incidences are below the three-year average. Afexa said Feb. 11 it hopes the Olympics bring added exposure to its products, as Cold-FX is the official cold and flu remedy of the Winter Games. Immunity-FX launched in late 2009 and is awaiting a Natural Product Number from Health Canada (1"The Tan Sheet" Nov. 30, 2009). Afexa plans to expand Immunity-FX into all retail channels in which Cold-FX currently sells

Sales & Earnings In Brief

Afexa rides flu concerns to record Q1: The maker of Cold-FX reports record revenue of $27.7 million (Canadian $29.5 million at Feb. 11 exchange rates), a 49.7 percent increase, during the quarter ended Dec. 31. Net earnings were also up substantially - 142.9 percent to $6.4 million - in Afexa Life Sciences' fiscal 2010 first quarter. Jack Moffatt, CEO of the Edmonton, Alberta, company, attributed increased sales of Cold-FX to public flu concerns, though "we expect demand to moderate in the second quarter" as cold and flu incidences are below the three-year average. Afexa said Feb. 11 it hopes the Olympics bring added exposure to its products, as Cold-FX is the official cold and flu remedy of the Winter Games. Immunity-FX launched in late 2009 and is awaiting a Natural Product Number from Health Canada (1"The Tan Sheet" Nov. 30, 2009). Afexa plans to expand Immunity-FX into all retail channels in which Cold-FX currently sells

Sales & Earnings In Brief

Afexa rides flu concerns to record Q1: The maker of Cold-FX reports record revenue of $27.7 million (Canadian $29.5 million at Feb. 11 exchange rates), a 49.7 percent increase, during the quarter ended Dec. 31. Net earnings were also up substantially - 142.9 percent to $6.4 million - in Afexa Life Sciences' fiscal 2010 first quarter. Jack Moffatt, CEO of the Edmonton, Alberta, company, attributed increased sales of Cold-FX to public flu concerns, though "we expect demand to moderate in the second quarter" as cold and flu incidences are below the three-year average. Afexa said Feb. 11 it hopes the Olympics bring added exposure to its products, as Cold-FX is the official cold and flu remedy of the Winter Games. Immunity-FX launched in late 2009 and is awaiting a Natural Product Number from Health Canada (1"The Tan Sheet" Nov. 30, 2009). Afexa plans to expand Immunity-FX into all retail channels in which Cold-FX currently sells

Related Content

Topics

UsernamePublicRestriction

Register

PS103515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel